Evidence map›Paper›PMID 40925374›Full record

ArticleCell reports. Medicine2025

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade.

Kabir A Khan, Maresa Caunt Mitzner, William Cruz-Munoz, Grant Li, Patricia Himmels, Ping Xu, Hung Yang Kuo, Raj Jesudason, Alvin Gogineni, Robby Weimer and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026
    Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kabir A KhanBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address: kabirkhanphd@gmail.com.
Maresa Caunt MitznerDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
William Cruz-MunozBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Grant LiDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
Patricia HimmelsDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
Ping XuBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Hung Yang KuoBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Raj JesudasonDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
Alvin GogineniDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
Robby WeimerDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA.
Annabelle ChowBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Robert PiskolDepartment of Oncology, Bioinformatics Genentech, South San Francisco, CA, USA.
Iacovos P MichaelBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Weilan YeDepartment of Molecular Oncology, Genentech Inc, South San Francisco, CA, USA. Electronic address: ye.weilan@gene.com.
Robert S KerbelBiological Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address: robert.kerbel@sri.utoronto.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The success of immune checkpoint inhibitors is limited by multiple factors, including poor T cell infiltration and function within tumors, partly due to a dense extracellular matrix (ECM). Here, we investigate modulating the ECM by targeting integrin α5β1, a major fibronectin-binding and organizing integrin, to improve immunotherapy outcomes. Use of a function-blocking murinized α5β1 antibody reduces fibronectin fibril formation, enhances CD8

Indexed as

Breast NeoplasmsExtracellular MatrixFibronectinsImmune Checkpoint InhibitorsAnimalsAntibodies, Monoclonal, HumanizedCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapyIntegrin alpha5beta1MiceAntibodies, Monoclonal, HumanizedatezolizumabFibronectinsImmune Checkpoint InhibitorsIntegrin alpha5beta1atezolizumabcancercombinationextracellular matrixfibronectinintegrin a5b1tumor immunotherapy

Identifiers

PMID40925374
PMCPMC12490255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.